- Home
- MTNB vs HSCS Comparison
MTNB vs HSCS Comparison
Compare MTNB & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- HSCS
- Stock Information
- Founded
- MTNB 2013
- HSCS 2007
- Country
- MTNB United States
- HSCS United States
- Employees
- MTNB N/A
- HSCS N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- HSCS Medical Specialities
- Sector
- MTNB Health Care
- HSCS Health Care
- Exchange
- MTNB Nasdaq
- HSCS Nasdaq
- Market Cap
- MTNB 3.0M
- HSCS 3.2M
- IPO Year
- MTNB N/A
- HSCS 2022
- Fundamental
- Price
- MTNB $0.58
- HSCS $3.17
- Analyst Decision
- MTNB Hold
- HSCS Strong Buy
- Analyst Count
- MTNB 1
- HSCS 2
- Target Price
- MTNB N/A
- HSCS $13.50
- AVG Volume (30 Days)
- MTNB 1.0M
- HSCS 15.1K
- Earning Date
- MTNB 03-26-2025
- HSCS 03-13-2025
- Dividend Yield
- MTNB N/A
- HSCS N/A
- EPS Growth
- MTNB N/A
- HSCS N/A
- EPS
- MTNB N/A
- HSCS N/A
- Revenue
- MTNB N/A
- HSCS $14,700.00
- Revenue This Year
- MTNB N/A
- HSCS $174.19
- Revenue Next Year
- MTNB N/A
- HSCS $4,100.00
- P/E Ratio
- MTNB N/A
- HSCS N/A
- Revenue Growth
- MTNB N/A
- HSCS 151.28
- 52 Week Low
- MTNB $0.48
- HSCS $2.36
- 52 Week High
- MTNB $21.50
- HSCS $18.50
- Technical
- Relative Strength Index (RSI)
- MTNB 43.31
- HSCS 39.08
- Support Level
- MTNB $0.53
- HSCS $3.11
- Resistance Level
- MTNB $0.70
- HSCS $3.45
- Average True Range (ATR)
- MTNB 0.06
- HSCS 0.17
- MACD
- MTNB 0.00
- HSCS -0.02
- Stochastic Oscillator
- MTNB 13.92
- HSCS 8.70
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.